Physician profile
Yen Phan
NPI 1811384878
$5,310.32
in general payments reported to CMS, 2019-2025
26 companies · $674 in 2025
The $674 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $945 · 2021: $491 · 2022: $1,187 · 2023: $819 · 2024: $655 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,128 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.98 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $834.10 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $778.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $569.87 | 2019-2025 | Shingrix, Arexvy |
| Novo Nordisk INC | $449.09 | 2020-2025 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $319.01 | 2020-2025 | Zoryve, Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $293.03 | 2021-2025 | |
| Lilly USA, LLC | $282.34 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Gilead Sciences, INC. | $252.57 | 2022-2024 | Vemlidy |
| Astellas Pharma US INC | $228.10 | 2022-2023 | Veozah |
| Redhill Biopharma INC. | $217.35 | 2021-2023 | |
| Amarin Pharma, INC. | $192.63 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $189.33 | 2019-2025 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.14 | 2020-2025 | Jardiance |
| Abbvie INC. | $107.53 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $94.13 | 2024 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $89.87 | 2022-2025 | |
| Medtronic, INC. | $35.62 | 2021 | |
| Abbott Laboratories | $35.32 | 2022-2024 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $26.25 | 2023 | Xarelto |
| Corcept Therapeutics | $23.06 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $22.12 | 2020 | |
| Exact Sciences Corporation | $20.78 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $18.92 | 2021 | |
| Hologic Sales and Service, LLC | $17.45 | 2023 | Aptima |
| Inari Medical, INC. | $14.04 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Nestle Healthcare Nutrition INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yen Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.